Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002
about
Delafloxacin, a non-zwitterionic fluoroquinolone in Phase III of clinical development: evaluation of its pharmacology, pharmacokinetics, pharmacodynamics and clinical efficacyStability of fluoroquinolone resistance in Streptococcus pneumoniae clinical isolates and laboratory-derived mutants.Comparative in vitro susceptibilities and bactericidal activities of investigational fluoroquinolone ABT-492 and other antimicrobial agents against human mycoplasmas and ureaplasmasIDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults.Ketolides: an emerging treatment for macrolide-resistant respiratory infections, focusing on S. pneumoniae.Molecular characterization of increasing fluoroquinolone resistance in Streptococcus pneumoniae isolates in Canada, 1997 to 2005.Daptomycin.Oritavancin and tigecycline: investigational antimicrobials for multidrug-resistant bacteria.Optimal dose finding of garenoxacin based on population pharmacokinetics/pharmacodynamics and Monte Carlo simulationClonal diversity and resistance mechanisms in tetracycline-nonsusceptible Streptococcus pneumoniae isolates in Poland.Limited spread of penicillin-nonsusceptible pneumococci, Skåne County, SwedenClinical update on linezolid in the treatment of Gram-positive bacterial infections.Antimicrobial resistance - Judicious use is the keyTigecycline: a new glycylcycline for treatment of serious infections.The search for new antimicrobials: why we need new options.Global fluoroquinolone resistance epidemiology and implictions for clinical use.Tigecycline: a novel glycylcycline antibiotic.Increasing genetic relatedness of ciprofloxacin-resistant Streptococcus pneumoniae isolated in Canada from 1997 to 2005.Faropenem medoxomil: a treatment option in acute bacterial rhinosinusitis.Increasing penicillin and trimethoprim-sulfamethoxazole resistance in nasopharyngeal Streptococcus pneumoniae isolates from Guatemalan children, 2001--2006.Treating acute exacerbations of chronic bronchitis and community-acquired pneumonia: how effective are respiratory fluoroquinolones?In Vivo Pharmacodynamic Target Assessment of Delafloxacin against Staphylococcus aureus, Streptococcus pneumoniae, and Klebsiella pneumoniae in a Murine Lung Infection Model.In vitro activity of Iclaprim against respiratory and bacteremic isolates of Streptococcus pneumoniae.Genomic characterization of ciprofloxacin resistance in a laboratory-derived mutant and a clinical isolate of Streptococcus pneumoniae.Designing fluoroquinolone breakpoints for Streptococcus pneumoniae by using genetics instead of pharmacokinetics-pharmacodynamics.Steady-state plasma and intrapulmonary pharmacokinetics and pharmacodynamics of cethromycin.Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates.Emerging drugs for pneumococcal pneumonia.Gemifloxacin: a new fluoroquinolone.Application of antimicrobial stewardship to optimise management of community acquired pneumonia.Resistance surveillance studies: a multifaceted problem--the fluoroquinolone example.Streptococcus pneumoniae infection: a Canadian perspective.Predicting and preventing antimicrobial resistance utilizing pharmacodynamics: Part I gram positive bacteria.Effect of utilization policies for fluoroquinolones: a pilot study in nova scotia hospitals.Mechanisms of macrolide resistance in clinical pneumococcal isolates in a university hospital, Ankara, Turkey.Whole-Genome Sequencing Reveals the Origin and Rapid Evolution of an Emerging Outbreak Strain of Streptococcus pneumoniae 12F.In Vitro Activity of Delafloxacin Tested against Isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.Minimal inhibitory and mutant prevention concentrations of azithromycin, clarithromycin and erythromycin for clinical isolates of Streptococcus pneumoniae.In vitro activity of garenoxacin against Streptococcus pneumoniae mutants with characterized resistance mechanismsPharmacodynamic activity of telithromycin at simulated clinically achievable free-drug concentrations in serum and epithelial lining fluid against efflux (mefE)-producing macrolide-resistant Streptococcus pneumoniae for which telithromycin MICs vary
P2860
Q26824268-3C9D4620-07FE-4B0C-B092-A1DD103354A0Q33807463-B169FCD7-1652-41BB-980C-70DD763D9648Q34230978-E332755A-FA13-4E09-88D2-2B89741CD4E3Q34262840-F2C9F7B9-71BB-487D-BFE4-9C30CC2D21C4Q34281970-8B836CAD-1D44-4BBF-B914-00779FB5289BQ35635780-08AB4AB3-6EB4-482E-9C12-F3922A46CDA3Q35637066-0A8DA0B7-D02C-4B01-B673-E51E3FEC5495Q35637071-3E6BCD97-0FAC-4649-8642-46808FB37704Q35644095-07F64AC2-C1BC-458A-873E-22AD0E5515A7Q35758970-DD93C960-9105-4083-B1C1-9000F1122D28Q35880428-F4B1AED1-21A5-4010-9FCE-7D33B155A7B5Q36083208-66A83626-8C6A-4878-8AFF-130318FCC77FQ36170892-D7C2D0EF-F03E-43DF-B978-2A9B8B1A4F92Q36218312-47A1F4BA-BB04-4224-ACD9-EA25605DFDEBQ36322113-8D7B85C1-8D45-4062-AE6F-97F5FFA7A0F7Q36337074-87FE0B46-1BC4-42FB-9889-A776907D27CCQ36379330-66AF5AF2-672D-427A-AC51-B285BCA28099Q36482793-83F9282F-16D7-480D-A0E2-124ED7146FACQ36688922-7BA9269C-3C36-4E8E-9704-9BF020999B04Q36726907-34448442-4D1B-4A73-9D79-642C7E372B5FQ36728602-85D5B832-4316-4131-9DAE-127044341F84Q37120092-3CC17626-73D4-4DC7-943D-C93935053DF7Q37144800-E5ACD5E1-04C1-4828-BD2E-A727E25515FBQ37263914-4B905025-D614-495A-8C83-BA7F962D316CQ37488687-7E959127-A2AF-4D6D-9CE3-817006CDFEE1Q37489476-3EE0C289-F7A0-4899-8F09-6E78F36CBD24Q37568953-434F61EB-FC7B-4C3A-84B9-0C4E4A301B1CQ37864327-3DCE31A1-6167-4452-A712-BAE699E91E2BQ37867123-A092331F-0CA1-4735-AA84-F312DD4A7109Q37890027-73857E0A-A402-4CDE-8A58-E4E8C26BAB33Q37998398-C6E63224-3377-491C-9163-088468FF55CDQ38131534-69318BF6-4D80-498B-87C2-F3596E734C75Q38692072-CCC40A19-C3F0-4B92-A3F3-88C61235B930Q39210974-73DD652C-E297-4A99-9475-E0BE89AE8BB2Q40430810-D9D04BDC-3378-4EEC-83D5-F98240C851FFQ40779865-F80D99A2-3447-47AC-8577-F2F851BFEC18Q41194442-B66BC500-8890-476E-BD13-1F2C27A5D3C7Q41785898-7E855F61-2FB8-4F70-86A3-0A2677CB6529Q41840910-AE9BAAAF-71FE-4D73-A3B1-69E03872E1A4Q42252396-F29D1230-4B49-4CBD-A481-6DBDF1B00E4E
P2860
Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Antimicrobial resistance in re ...... eptibility Study, 1997 to 2002
@ast
Antimicrobial resistance in re ...... eptibility Study, 1997 to 2002
@en
type
label
Antimicrobial resistance in re ...... eptibility Study, 1997 to 2002
@ast
Antimicrobial resistance in re ...... eptibility Study, 1997 to 2002
@en
prefLabel
Antimicrobial resistance in re ...... eptibility Study, 1997 to 2002
@ast
Antimicrobial resistance in re ...... eptibility Study, 1997 to 2002
@en
P2093
P2860
P1476
Antimicrobial resistance in re ...... eptibility Study, 1997 to 2002
@en
P2093
Daryl J Hoban
Kimberly A Nichol
Lorraine Palatnick
Tracy Bellyou
P2860
P304
P356
10.1128/AAC.47.6.1867-1874.2003
P407
P577
2003-06-01T00:00:00Z